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DOI 10.1016/j.stem.2008.08.012Determining when it is ethically appropri-
ate to use existing human embryonic
stem cell (hESC) lines can be challenging
for scientists as well as oversight bodies.
Here, we identify such challenges and of-
fer an approach to addressing them.
Various guidelines have been issued
regarding the ethical oversight of human
embryonic stem cell research. For exam-
ple, the National Academies of Sciences
(NAS) issued guidelines in 2005, with
amendments in 2007 (Committee on
Guidelines for Embryonic Stem Cell Re-
search, National Research Council, 2005;
Human Embryonic Stem Cell Research
Advisory Committee, National Research
Council, 2007). The International Society
for Stem Cell Research (ISSCR) also re-
leased guidelines in 2006 (International
Society for Stem Cell Research, 2006).
Both sets of guidelines call for oversight
of this research by ESCROs (Embryonic
StemCellResearchOversight committees,
under NAS) or SCROs (Stem Cell Research
Oversight mechanisms, under ISSCR).
The guidelines include a variety of pro-
visions depending upon the type of re-
search being proposed. While both sets
of guidelines place considerable empha-
sis on provisions for deriving new hESC
lines, they also suggest truncated review
of research that involves the use of exist-
ing hESC lines. Much of the review pro-
cess described in the guidelines focuses
on the provenance of the hESC lines.
The NAS indicates that the review pro-
cess must involve ‘‘documentation of the
provenance of the cell lines including:
(i) documentation of the use of an accept-
able informed consent process that was
approved by an Institutional Review
Board or foreign equivalent for their deri-
vation . . . and (ii) documentation of com-
pliance with any additional required
review by an Institutional Animal Care238 Cell Stem Cell 3, September 11, 2008 ª2and Use Committee (IACUC), Institutional
Biosafety Committee (IBC), or other insti-
tutionally mandated review’’ (Human Em-
bryonic Stem Cell Research Advisory
Committee, National Research Council,
2007). Under ISSCR’s guidelines, the re-
view process must ‘‘include a determina-
tion that the provenance of the human
embryonic stem cell lines to be used has
been scrutinized and deemed acceptable
according to the principles outlined in this
document, and that such research is in
compliance with scientific, legal, and
ethical norms’’ (International Society for
Stem Cell Research, 2006).
Despite what seems to be consensus
regarding the need to assess provenance,
neither of these guidelines explicitly de-
fines the specific use of the term itself. A
common dictionary definition of ‘‘prove-
nance’’ denotes origin or source, or ‘‘the
history of ownership of a valued object’’
(see Merriam-Webster Online). However,
the guidelines intimate that the task is
more comprehensive, involving informa-
tion about gamete and embryo donors,
the physical settings in which biological
materials were obtained, and the pres-
ence and nature of any ethical or other in-
stitutional oversight involved. Further, the
guidelines imply that oversight commit-
tees make ethical judgments concerning
the information about provenance that is
obtained. Nevertheless, little guidance is
offered regarding how to make such as-
sessments. This lack of specific direction
can leave scientists uncertain about which
cell lines might be appropriate to use in
their research and puts oversight commit-
tees in a challenging position when they
are asked to make such determinations
on behalf of the researchers (e.g.,
Streiffer, 2008).
We developed a stepwise approach to
aid in determining whether a proposed008 Elsevier Inc.use of a given hESC line is appropriate
(Figure 1). The approach assumes that
due diligence is exercised in obtaining
the information necessary to conduct an
assessment of provenance. When a spe-
cific use is proposed, it can easily be per-
mitted if the evidence indicates that the
hESC line was derived consistent with
current standards. In contrast, if a prelimi-
nary review provides (1) evidence indicat-
ing a prima facie failure to satisfy current
guidelines or (2) a lack of evidence that
practices adhered to current guidelines,
then deliberation is required. Delibera-
tions involve consideration of the underly-
ing ethical principles in context.
Contextual features should help deter-
mine whether to make an exception to
the current guidelines and permit the pro-
posed use. Contextual features may in-
clude articulated policy statements or
laws, information about the research envi-
ronment, and information about the set-
ting in which the embryos used in hESC
research were created. Note that this
approach does not necessarily rely solely
upon published and available documen-
tation of consent and review procedures.
While such documents, if available, may
facilitate the review process, a robust ev-
identiary base may arguably include other
information. For instance, discussion with
experts in the field may provide evidence
of acceptable standards in place at the
time, or of local review processes that
were utilized. A central question to ad-
dress during deliberation is whether the
ethical principles underlying provisions
of extant and current guidelines are vio-
lated by permitting use.
An example should help make this
clear. An investigator approached our
ESCRO about using hESC lines from
Stemride International. We obtained
published information about the lines in
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LetterFigure 1. Proposed Approach to Determine Acceptable Uses of hESCs, According to Their
Provenance
Schema to aid ESCROs, SCROs, and researchers in determining whether a proposed use of a given hESC
line is ethically appropriate. Contextual features may include: (1) articulated policy statements or laws, (2)
information about the research environment, and (3) other related sources.question, as well as a copy of the informed
consent document that was used with em-
bryo donors, and minutes from the institu-
tional review board that reviewed the pro-
posed research. We also consulted with
the investigator who derived the lines to
resolve some questions not answerable
with these materials.
Careful examination of the information
acquired yielded no evidence that the
consent process informed embryo do-
nors that their embryos would be de-
stroyed in the course of creating the
hESC lines, which is a required provision
in current guidelines for hESC research.
In other words, there was prima facie evi-
dence that the standards for hESC re-
search were not adhered to, resulting in
the need for deliberation that would take
into account the relevant contextual fea-
tures. One important contextual feature
is the articulated ethics guidance that ex-
isted at the time the lines were derived. Ifsuch guidance was indeed satisfied, then
even if current guidelines are more strin-
gent, and thus not satisfied, it may yet
be permissible to use the lines. That is,
provided that investigators acted sub-
stantially in accord with underlying ethical
principles (e.g, respect for autonomy), ad-
herence to the less stringent guidelines
may be considered sufficient. In this par-
ticular case, however, the extant guid-
ance documents clearly required that do-
nors understood that the embryos would
be destroyed in the process of deriving
hESC lines. This point provided further
support for the prima facie claim disallow-
ing the use of the Stemride hESC lines.
Nevertheless, we next considered the set-
ting in which the embryos were gener-
ated. In this example, the embryo donors
were recruited from a clinic that was utiliz-
ing preimplantation genetic diagnosis; the
hESC lines were derived using either ‘‘dis-
eased’’ or ‘‘healthy’’ embryos. Arguably,Cell Stem Cell 3, Sdonors who were involved in using preim-
plantation genetic diagnosis to select em-
bryos would not be expected to be mor-
ally opposed to destruction of those
embryos with genetic abnormalities; how-
ever, it is unclear whether the donors
would feel similarly about those embryos
that could potentially be used for in vitro
fertilization. Based on these contextual
features, our ESCRO decided that the in-
vestigator could use the diseased hESC
lines consistent with the ethical principles
underlying the standards for hESC re-
search, but not the healthy lines.
The systematic approach to assessing
provenance information about hESC lines
we describe here should be helpful to
SCROs and ESCROs in making determi-
nations concerning the ethical use of par-
ticular cell lines. An advantage of this ap-
proach is that it makes the processes of
practical and moral reasoning more
explicit. As additional experience is gar-
nered the approach may need to be mod-
ified and adjusted.
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